Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05987475

Prospective Observational Clinical Follow-up of Euromi Biosciences Pre-filled Silicone Gel Breast Implants

Prospective observational clinical follow-up of Euromi Biosciences silicone gel-filled breast implants - Post-market clinical investigation - ELEGANT

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Implant Rupture Breast Implant; Complications

Age range

18 year–60 year

Sex eligibility

Female

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female;
  • 18 years old and above, and under 60 years old;
  • has approved and signed the informed consent form;
  • eligible to receive at least one EUROMI Biosciences implant during breast reconstruction following a mastectomy or during aesthetic breast surgery;
  • Willing to be followed up for a period of 10 years.

Exclusion criteria

  • Informed pregnancy or breastfeeding at the time of inclusion
  • Known hypersensitivity and / or allergy to silicone;
  • Not understanding or not accepting the risks of further surgeries during follow-up;
  • Body mass index > 40 kg/m²;
  • Diabetes
  • HbA1c levels > 7,5%;
  • History of repeated failure with the implantation of similar implants;
  • Tissue or fat insufficiency;
  • Progressive breast cancer large tumours (>5 cm), late cancer stage and deep tumours;
  • Grossly positive axillary involvement / or chest wall involvement;
  • High risk of cancer recurrence;
  • Tissue damage in the implant area due to irradiation of the thoracic wall;
  • Pre-existing pathology in the implant area;
  • General infection or infection in the implant area;
  • Medical condition (poor physiological condition, psychological instability, severe smoking, obesity, coagulopathy, diabetes, severe cardiovascular or pulmonary disease, etc.) Which may, according to the judgement of the surgeon, entail excessive risk and/or post-surgical complications;
  • History or presence of an autoimmune disease;
  • Immunocompromised;
  • History or current treatment using radiation with lower-pole scarring and thin, poorly vascularized skin/tissue / microwave diathermy / or steroids;
  • Medical condition likely to interfere with her capacity to understand the follow-up requirements, to participate in the follow-up or to give her informed consent;
  • Concomitantly part of another interventional clinical trial.
  • Under supervision or legal guardianship
  • Deprived of liberty by a judicial or administrative decision
  • Not affiliated to health insurance system or is a beneficiary of such coverage

Treatment and study plan

Breast reconstruction

Procedure

Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation

Other names: Breast augmentation

Primary outcomes

  1. Rate of capsular contracture

    Time frame: From implantation to end of study (10-year)

    To describe the rate of capsular contracture. Capsular contracture will be evaluated according to the Baker classification (from I to IV with grade III/IV considered as retractile capsular contractures).

  2. Post-surgery rupture

    Time frame: From implantation to end of study (10-year)

    To describe the rate of post-surgery rupture. Rupture will be evaluated based on cases of hardening or deflation, based on clinical signs and if deemed necessary by the investigator, by medical imaging (mammography, ultrasound, MRI).

Secondary outcomes

  1. Participant's QoL

    Time frame: From implantation to end of study (10-year)

    Quality of life: will be evaluated using the French version of the Breast Body Image Scale (BBIS).

  2. Breast implant survival rate.

    Time frame: From implantation to end of study (10-year)

    Breast implant survival rate: the event will be defined as the removal of a breast implant for any reason other than participant's wish. Breast survival will be defined as the absence of breast implant removal. The analysis will be at the implant level and at the participant level, overall and by group.

  3. Frequency of occurrence of other adverse events and complications

    Time frame: From implantation to end of study (10-year)

    Evaluate the frequency of occurrence of other adverse events and complications recorded during the study

  4. Participant's and investigator's satisfaction regarding the aesthetic result

    Time frame: From implantation to end of study (10-year)

    Participant and investigator satisfaction with aesthetic results: questionnaire using generic 6-level Likert scale: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, somewhat satisfied, very satisfied, extremely satisfied.

  5. Reoperation rate

    Time frame: From implantation to end of study (10-year)

    Reoperation will be defined as a new operation at the breast implant site for any cause.

    The analyses will be performed at the implant level and at the participant level, overall and by group

Sponsors and collaborators

Lead sponsor

Euromi Biosciences

Industry

Registry information

Acronym: ELEGANT

Important dates

Study start
2023
Primary completion
2034
Study completion
2034
First posted
Aug 14, 2023
Registry last updated
Nov 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.